Prothrombine and activated partial thromboplastin time are prolonged in hepatic cirrhosis

  title={Prothrombine and activated partial thromboplastin time are prolonged in hepatic cirrhosis},
  author={Edward Kurnia Setiawan Limijadi and Lisyani B. Suromo and Imam Budiwiyono},
Background Chronic hepatitis and hepatic cirrhosis are chronic liver diseases that cause disorders of liver function, such as the formation of platelets and coagulation factors (prothrombin time/PT and activated partial thromboplastin time/APTT). Chronic hepatitis in the long term can develop into hepatic cirrhosis. The aim of this study was to determine platelet count, PT, and APTT as indicators in the progression of chronic hepatitis towards hepatic cirrhosis. Metho d s A cross-sectional… 
2 Citations

Tables from this paper

Prothrombin Time Activated Partial Thromboplastin Time and Platelets Count among Hypertensive Patients Attending a Tertiary Health Institution in Yenagoa, Nigeria
There is need for early diagnosis to avoid hemostatic complications and to aid effective management of the patients, as there were significant variations between the hypertensive and control subjects for each of the parameters.
Assessment of Some Haemostasis System BloodIndicators among the Elderly Attending a tertiaryHealth Institution in Nigeria
The pro-thrombin time, activated partial thromboplastin time showed a significant increase while blood platelets showed significant decline with ageing, which suggests possible by functioning with “ dysfunctioning of the haemostatic system.


Assessment of platelets count and coagulation parameters among Sudanese patients with liver cirrhosis
Assessing the haemostatic defects in patients of liver cirrhosis by estimating prothrombin time (PT), activated partial thromboplastin time (APTT), plasma fibrinogen level, fibr inogen degradation products (D-dimer), and platelet count found that platelets count in cirrhotic patients was significantly lower than the normal range.
Prolongation of PT and APTT indicates plasma clotting factors deficiency due to impaired hepatic synthesis, andDerangements of other coagulation parameters indicate that multiple factors like fibrinolysis, hypofibrinogenaemia, thrombocytopenia, and low grade DIC, all play a role in liver cirrhosis.
Thrombocytopenia in chronic hepatitis C.
Chronic hepatitis C is associated with a variable degree of thrombocytopenia and, in most cases, both mechanisms are involved.
Prothrombin time in patients with and without fibrotic chronic liver disease
Prothrombin time and international normalized ratio strongly correlate with fibrosis in chronic liver disease.
New insights into the coagulopathy of liver disease and liver transplantation.
The liver is an essential player in the pathway of coagulation in both primary and secondary haemostasis, but recently it has been shown that the delicate balance between pro and antithrombotic factors synthetised by the liver might be reset to a lower level in patients with chronic liver disease.
Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease
Investigation of platelet count in chronic liver disease patients seen at the gastroenterology unit of the University of Nigeria Teaching Hospital Ituku/Ozalla found abnormalities of platelets occur in HBV-related liver disease, and thrombocytosis may be a paraneoplastic manifestation of HCC.
Thrombocytopenia associated with chronic liver disease.
Coagulopathies in Patients with Liver Cirrhosis
PT and APTT were significantly raised in cirrhotic patients and the frequency of Coagulation abnormalities in patients with cirrhosis of liver was evaluated.
Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No
  • P. Mannucci
  • Medicine
    Journal of thrombosis and haemostasis : JTH
  • 2006
How the recent adoption of he mostasis tests more capable than those used so far to reflect in vitro what is happening in vivo challenges the dogma that hemostasis is abnormal in patients with chronic liver disease is demonstrated.
Hemostatic defects in end stage liver disease.